Purchase this article with an account.
H. Sakaguchi, Y. Oshima, M. Sawa, M. Tsujikawa, F. Gomi, Y. Ikuno, M. Kamei, S. Kusaka, Y. Tano; Clinical Studies of Intravitreal Injection of Bevacizumab (Avastin®) for Rubeosis Associated With Proliferative Diabetic Retinopathy . Invest. Ophthalmol. Vis. Sci. 2006;47(13):3841.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy and short–term safety of intravitreal injection of bevacizumab (Avastin® ) in patients with rubeosis associated with proliferative diabetic retinopathy.
Off–label, single–center, uncontrolled clinical study.
Intravitreal injection of bevacizumab (1mg) was conducted in a consecutive series of 3 eyes with rubeosis iridis associated with proliferative diabetic retinopathy which poorly responded to laser photocoagulation and vitrectomy. Pre–injection parameters (visual acuity / intraocular pressure [mmHg]) in the 3 eyes were 0.3/30, 0.1/32, and 0.2/14, respectively. Ophthalmic examination, including visual acuity and intraocular pressure measurements, were conducted 1 day, 1 week, and 1 month after injection. Regression of rubeosis was evaluated based on slit–lamp examination with gonioscopy and fluorescein angiography.
Rubeosis iridis had regressed in 2 eyes (67%) and disappeared completely in 1 eye (33%) from 1 week following injection. Visual acuity remained stable without recurrence of rubeosis and the intraocular pressure was also unchanged for at least 1 month. No inflammation and endophtahlmitis were observed.
Intravitreal injection of bevacizumab may provide an effective and safe alternative for patients with diabetic rubeosis refractory to conventional treatments.
This PDF is available to Subscribers Only